MD Anderson Cancer Center at Cooper

Cooper University Hospital

Camden, NJ

Sorting 4 by

Accepting patients

MajesTEC-9

Phase 3 Clinical Trial Comparing a Study Medication Alone Versus Pomalidomide, Bortezomib, Dexamethasone or Carfilzomib and Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma
Learn more
  • Bispecific Antibody
  • BCMA
  • Randomization
  • Phase 3

Not yet accepting

Selinexor

Phase 3 Clinical Trial Comparing the Safety and Effectiveness of Selinexor, Pomalidomide and Dexamethasone vs Elotuzumab, Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma
Learn more
  • SINE
  • Randomization
  • Phase 3

Accepting patients

DRAMMATIC

S1803, Lenalidomide +/- Daratumumab/rHuPh20 as Post-ASCT Maintenance for MM w/MRD to Direct Therapy Duration (DRAMMATIC)
Learn more
  • Monoclonal Antibody
  • CD38
  • Maintenance
  • Phase 3

Not yet accepting

MajesTEC-7

A Study to Compare Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) in Participants With Newly Diagnosed Multiple Myeloma (MajesTEC-7)
Learn more
  • Bispecific Antibody
  • BCMA
  • Randomization
  • Phase 3
1 hidden based on your filters. Show All